Current stock page

Stock Analysis

Definium Therapeutics, Inc. (DFTX) Stock Analysis

Definium Therapeutics, Inc. (DFTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

DFTX Stock Analysis Summary

Definium Therapeutics, Inc. (DFTX) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 64/100. Risk is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

DFTX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$32.08
AIQ Score59/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$4.36B
P/E Ratio (TTM)-10.59
Forward P/E—
EPS (Q3 FY2026)-$0.37
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.14
Volume778.19K
52-week range$10.46-$49.70
RSI 1441.55
50-Day SMA$36.07
200-Day SMA$30.43
Analyst Price Target$75.50
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

DFTXDefinium Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$32.08−$0.92 (−2.79%)

Latest quote

  • Momentum
    64
  • Value
    —
  • Quality
    60
  • Risk resilience
    44
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

DFTX Stock Analysis Summary

Definium Therapeutics, Inc. (DFTX) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 64/100. Risk resilience is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, DFTX has AIQ Score of 59/100 with Momentum base of 64/100 and fading Risk resilience at 44/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (64/100) leads while Risk resilience (44/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.79% stock move · DFTX classified in Biotechnology.

Current Evidence

NeutralDFTX is in a neutral AIQ regime; Momentum is the strongest visible factor at 64/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is DFTX Bullish or Bearish Right Now?

DFTX currently has a neutral overall setup. Momentum is the strongest factor at 64/100, while Risk Resilience is weakest at 44/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Analyst target implies +135.35% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 44/100.
  • - Technical consensus has more sell votes than buy votes (35 vs 4).

Current Consensus

DFTX's Technical Analysis Consensus is currently Strong Sell, with 4 buy, 7 neutral, and 35 sell votes. DFTX's 14-day RSI is 41.55, which places the stock in a weaker momentum range. DFTX's beta is 1.14, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in DFTX?

The largest recent change in DFTX is Quality moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+0.0
Momentum
-2.0
Quality
+3.0
Risk
+0.0

What Would Change the DFTX Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

DFTX Decision Framework

Public evidence layers, setup checks, and risk context for Definium Therapeutics, Inc..

Definium Therapeutics, Inc. (DFTX) Stock Analysis

Definium Therapeutics, Inc. has an AIQ Score of 59/100 in a Neutral regime. Momentum is strongest at 64/100. Beta is 1.14, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextDFTX is in a Neutral AIQ regime with score 59/100.
Signal ConflictThe primary conflict is that momentum leads at 64/100 while risk lags at 44/100.
Factor EvidenceMomentum 64/100 · Quality 60/100 · Risk 44/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 64/100.

TimingWait

Momentum is 64/100 and RSI (14) is 41.6.

Regime fitWait

DFTX is in a Neutral regime at 59/100.

Risk controlFail

Risk factor is 44/100 with beta 1.14 and annual volatility 77.71%.

ConflictWait

Current conflict: momentum leads at 64/100 while risk lags at 44/100.

AIQ Score
59/100
Price
$32.08
Beta
1.14
RSI (14)
41.6

DFTX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

DFTX Fundamentals

DFTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$50.96M
Free cash flow
-$52.98M
View full DFTX fundamental analysis

DFTX Technical Analysis

DFTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
41.55
Price vs SMA-50
-11.06%
View full DFTX technical analysis

DFTX Stock Catalysts

Track DFTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$75.50
News items
0
View DFTX earnings and stock catalysts

DFTX Dividend Analysis

DFTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View DFTX dividend history and analysis

DFTX Financial Data

DFTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.37
Periods
8
View DFTX financials

DFTX Risk Analysis

DFTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.14
Risk score
44/100
1Y volatility
77.71%
View DFTX risk analysis

DFTX Stock News

DFTX stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read DFTX stock news

DFTX vs Biotechnology Peers

Current peer cohort: DFTX · DNTH · DYN · ELVN · ERAS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
DFTX
Current stock
59/100—64/10044/1001.6177.71%Current
DNTH
Dianthus Therapeutics, Inc.
56/100—58/10058/1001.8259.79%DFTX vs DNTH
DYN
Dyne Therapeutics, Inc.
48/100—52/10042/1000.1163.89%DFTX vs DYN
ELVN
Enliven Therapeutics, Inc.
71/100—66/10056/1001.4378.19%DFTX vs ELVN
ERAS
Erasca, Inc.
61/100—67/10039/1002.29102.70%DFTX vs ERAS
Pairwise Compare links: DNTH · DYN · ELVN · ERASDFTX vs DNTHDFTX vs DYNDFTX vs ELVNDFTX vs ERASCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a DFTX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for DFTX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-10.59
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.04
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$50.96M
Quarter free cash flow
-$52.98M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
41.55
MACD
-0.89

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
44/100
Beta
1.14
Annual volatility
77.71%
Max drawdown
-37.34%

DFTX Stock FAQ

What is DFTX stock price today?

Definium Therapeutics, Inc.'s current stock price is $32.08. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is DFTX bullish or bearish right now?

DFTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is DFTX's market cap?

DFTX's market cap is $4.36B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is DFTX's current P/E ratio?

DFTX's current P/E ratio is -10.59 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is DFTX's RSI?

DFTX's 14-day RSI is 41.55 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is DFTX above its 50-day and 200-day moving averages?

DFTX is -11.06% from its 50-day SMA and 5.43% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is DFTX's next earnings date?

DFTX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does DFTX pay a dividend?

DFTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.